A Cannabinoid Support Nonprofit: What It Says It Does, and What the Clinical Evidence Shows

As of August 20, 2026, the Realm of Caring says it provides cannabinoid information, research, education, advocacy, grants, and free one-on-one support.

By Cannible Editorial

2026-08-08

As of August 20, 2026, the Realm of Caring says it provides cannabinoid information, research, education, advocacy, grants, and free one-on-one support. Clinical reviews, however, describe a more limited and condition-specific evidence base: small to modest benefits for some indications, inconclusive evidence for mental disorders and other conditions, and meaningful uncertainty about harms and long-term outcomes. This position can change as research and regulations develop. 1 2 3

This article is general information, not individualized legal, medical, business, or compliance advice. Whether any of it applies to a particular person, product or business depends on the facts and on applicable state law; consult a qualified professional.

What the organisation says it does

The organisation states that it is a 501(c)(3) nonprofit founded in 2013. It says its work is intended to serve people seeking information about cannabinoid therapies, healthcare providers, and participants in the hemp and cannabis industries through research, education, advocacy, community support, and grants. 1

The organisation states that it offers research information, educational material, and free one-on-one help by phone, email, or appointment. It also says it assists pediatric and adult clients, as well as pets, and that its support is available to clients worldwide. 1

The organisation says it funds and collects research, educates consumers and healthcare professionals about accumulated research, and helps clients choose products and locate places to purchase them. It also states that it does not sell or distribute products, although it provides information about product lines and product-quality considerations. 1

The organisation reports having served more than 100,000 clients worldwide with one-on-one support, aided efforts associated with medicinal-cannabis legislation in 22 states, and enrolled more than 5,000 participants in observational research studies. These figures are statements by the organisation about its own activities; they do not demonstrate that cannabinoid products work or are safe. 1

What its own material does and does not show

The organisation’s website describes reported benefits of CBD and THC across a long list of conditions and effects, and says that people with the same condition may have different outcomes. It also says that finding a suitable product can involve trial and error. Those statements describe the organisation’s position and service approach, not results from a controlled clinical trial. 1

The organisation states that it maintains a research library containing hundreds of peer-reviewed articles and directs readers to search it by condition or cannabinoid. A library or observational programme can help identify research questions, but the material cited here does not establish that a particular product, formulation, or approach improves a particular person’s outcome. 1

The organisation’s own FAQ acknowledges that potential drug interactions exist and says there is not enough evidence to determine the absolute safety of cannabis, hemp, or CBD for some special populations, including pregnancy, nursing, and some psychiatric conditions. It also says that CBD products may contain trace THC and that this can produce a positive drug-screen result. 1

What the broader clinical review found

A review of evidence on medical cannabis and cannabinoids concluded that herbal cannabis and cannabinoid medicines, often used alongside standard medicines, may produce small to modest benefits primarily for chronic pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and refractory epilepsy when CBD is used. The same review found the evidence inconclusive for mental disorders and other medical conditions. 2

That review described cannabis-based medicine as generally well tolerated, but it also identified a risk of mild to moderate adverse effects and cannabis use disorder. Its discussion of nonmedical use reported that acute high-THC exposure can cause time-limited mental, gastrointestinal, and cardiovascular problems and motor-vehicle accidents. Repeated high-THC use has been associated with several adverse outcomes, particularly among adolescents and young adults, although the review noted debate about how much cannabis use causes those outcomes. 2

The clearest condition-specific evidence here: chronic pain

A systematic review and meta-analysis of 32 randomized clinical trials involving 5,174 adults found that non-inhaled medical cannabis or cannabinoids produced small to very small improvements compared with placebo in pain relief, physical functioning, and sleep quality among people with chronic pain. The pain analysis estimated a 10% difference in the proportion achieving a minimally important improvement, based on a 0.50-centimeter difference on a 10-centimeter pain scale. 3

The same analysis found no improvement in emotional, role, or social functioning. It found increased risks of several transient effects, including cognitive impairment, vomiting, drowsiness, impaired attention, nausea, and dizziness. The estimated increase in dizziness was higher in trials with at least three months of follow-up than in shorter trials. 3

The pain evidence has boundaries. Thirty of the 32 trials used oral treatment and two used topical treatment; the analysis did not establish results for inhaled products. Follow-up ranged from one to 5.5 months, and the review focused on adult participants with chronic non-cancer or cancer-related pain. Its conclusion was therefore about the studied interventions and populations, not every cannabinoid product or every person with pain. 3

Federal United States regulatory context

Under United States federal law, the 2018 Farm Bill defined hemp as Cannabis sativa L. and its derivatives containing no more than 0.3% delta-9 THC by dry weight, and removed hemp within that definition from the federal Controlled Substances Act. The same law preserved the federal Food and Drug Administration’s authority over products containing cannabis or cannabis-derived compounds under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act. 4

For the United States, the FDA states that it has not approved a marketing application for cannabis to treat any disease or condition. It has approved one cannabis-derived and three cannabis-related drug products, and those products are available only by prescription from a licensed healthcare provider. 4

The federal position does not resolve every question about products sold in a particular place. The evidence here does not provide a state-by-state legal analysis, does not establish rules for international travel, and does not establish whether a specific retail product is lawful or appropriately labeled in a particular jurisdiction. 1 4

How to read the claims alongside the evidence

The organisation’s stated services may be useful for locating research, education, and support, but its programme descriptions, client counts, observational research, and testimonials do not by themselves establish efficacy or safety. The clinical evidence in this pack supports a narrower conclusion: some non-inhaled cannabinoid interventions may provide limited relief or functional benefits for certain adults with chronic pain, while adverse effects occur and evidence for many other conditions remains inconclusive or limited. 1 2 3

A decision involving a prescription cannabinoid medicine belongs with a licensed healthcare provider, as reflected in the United States federal prescription status of the approved products. Questions about possession, purchase, shipping, or travel require checking the specific jurisdiction involved because the evidence here does not supply a complete jurisdiction-by-jurisdiction answer. 1 4